{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:11:34Z","timestamp":1790881894150,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoanabolic therapies such as parathyroid hormone (PTH) analogs (teriparatide [TPT], abaloparatide [ABL]) and the sclerostin inhibitor romosozumab rapidly stimulate new bone deposition but their bone-building effects are not indefinite. Clinical trials including bone turnover markers and bone histomorphometry studies show that the initial gains in bone formation and density wane with continued therapy\u2014typically within 12-18 mo for PTH analogs and even sooner for romosozumab. This invited review explores the biological mechanisms that may explain this waning response, including receptor desensitization at the PTH1 receptor level, depletion or saturation of bone-forming surfaces, exhaustion or downregulation of osteoblast progenitors, upregulation of endogenous Wnt pathway antagonists (eg, sclerostin, DKK1), and mechanostatic feedback from increased bone mass. The contrasting kinetics of TPT, ABL, and romosozumab are compared, highlighting how their modes of action (remodeling- vs modeling-based formation) influence the duration of anabolic activity. Finally, potential strategies to extend or rekindle anabolic effects are discussed\u2014including sequential and combination therapies and adjunctive mechanical loading\u2014with a view toward maximizing bone gains and reducing fracture risk. Understanding why anabolic drug efficacy attenuates provides insight into bone biology and guides the design of regimens to achieve more sustained increases in bone mass and strength.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag053","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:29:04Z","timestamp":1773664144000},"page":"915-921","source":"Crossref","is-referenced-by-count":2,"title":["Mechanisms underlying the waning of osteoanabolic therapy effects in osteoporosis"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-4417","authenticated-orcid":false,"given":"Serge","family":"Ferrari","sequence":"first","affiliation":[{"name":"Service of Bone Diseases, Department of Medicine, Geneva University Hospital and Faculty of Medicine , Gen\u00e8ve, CH-1205 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-1825","authenticated-orcid":false,"given":"Cyril","family":"Thouverey","sequence":"additional","affiliation":[{"name":"Service of Bone Diseases, Department of Medicine, Geneva University Hospital and Faculty of Medicine , Gen\u00e8ve, CH-1205 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3653-9046","authenticated-orcid":false,"given":"Maude","family":"Gerbaix","sequence":"additional","affiliation":[{"name":"Service of Bone Diseases, Department of Medicine, Geneva University Hospital and Faculty of Medicine , Gen\u00e8ve, CH-1205 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"1","key":"2026082903272089900_ref1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11657-024-01441-z","article-title":"Similarities and differences between European guidelines for the management of postmenopausal osteoporosis","volume":"19","author":"Cortet","year":"2024","journal-title":"Arch Osteoporos"},{"issue":"16","key":"2026082903272089900_ref2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"10117","key":"2026082903272089900_ref3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet."},{"issue":"7","key":"2026082903272089900_ref4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA."},{"issue":"19","key":"2026082903272089900_ref5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"15","key":"2026082903272089900_ref6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"9999","key":"2026082903272089900_ref7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet."},{"issue":"7","key":"2026082903272089900_ref8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"15","key":"2026082903272089900_ref9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"issue":"4","key":"2026082903272089900_ref10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.3350","article-title":"Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026082903272089900_ref11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97(2)","author":"Moreira","year":"2017","journal-title":"Bone."},{"issue":"9","key":"2026082903272089900_ref12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026082903272089900_ref13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2026082903272089900_ref14","doi-asserted-by":"publisher","first-page":"100291","DOI":"10.1016\/j.bonr.2020.100291","article-title":"Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice","volume":"13","author":"Arlt","year":"2020","journal-title":"Bone Rep"},{"issue":"1","key":"2026082903272089900_ref15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology."},{"issue":"6","key":"2026082903272089900_ref16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2026082903272089900_ref17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026082903272089900_ref18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jbmr.4193","article-title":"Mechanically driven counter-regulation of cortical Bone formation in response to sclerostin-neutralizing antibodies","volume":"36","author":"Gerbaix","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"42","key":"2026082903272089900_ref19","doi-asserted-by":"publisher","first-page":"29968","DOI":"10.1074\/jbc.274.42.29968","article-title":"Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2. Real-time monitoring by fluorescence microscopy","volume":"274","author":"Ferrari","year":"1999","journal-title":"J Biol Chem"},{"issue":"1","key":"2026082903272089900_ref20","doi-asserted-by":"publisher","first-page":"1ps","DOI":"10.1126\/scitranslmed.3000268","article-title":"Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation","volume":"1","author":"Ferrari","year":"2009","journal-title":"Sci Transl Med"},{"issue":"50","key":"2026082903272089900_ref21","doi-asserted-by":"publisher","first-page":"38181","DOI":"10.1074\/jbc.M606762200","article-title":"Proline-rich motifs in the parathyroid hormone (PTH)\/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1\/2 activation","volume":"281","author":"Rey","year":"2006","journal-title":"J Biol Chem"},{"issue":"41","key":"2026082903272089900_ref22","doi-asserted-by":"publisher","first-page":"38524","DOI":"10.1074\/jbc.M202544200","article-title":"Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations","volume":"277","author":"Bisello","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"2026082903272089900_ref23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2017.11.003","article-title":"Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists","volume":"107","author":"Holdsworth","year":"2018","journal-title":"Bone."},{"issue":"10","key":"2026082903272089900_ref24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176558","article-title":"Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells. JCI","volume":"9","author":"Thouverey","year":"2024","journal-title":"Insight."},{"key":"2026082903272089900_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.783","article-title":"Increase in serum DKK1 levels attenuates the anabolic response to Romosozumab in postmenopausal osteoporosis","volume":"84","author":"Adami"},{"issue":"11","key":"2026082903272089900_ref26","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026082903272089900_ref27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2016.11.009","article-title":"Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study","volume":"95","author":"Tsai","year":"2017","journal-title":"Bone."},{"issue":"5","key":"2026082903272089900_ref28","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2010-2552","article-title":"The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1","volume":"96","author":"Gatti","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026082903272089900_ref29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone."},{"issue":"12","key":"2026082903272089900_ref30","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026082903272089900_ref31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ar.a.10119","article-title":"Bone's mechanostat: a 2003 update","volume":"275","author":"Frost","year":"2003","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"issue":"Suppl 1","key":"2026082903272089900_ref32","first-page":"15","article-title":"Potential and limitations of bone anabolic therapy with PTH","volume":"1","author":"Gasser","year":"2003","journal-title":"Arthr & Bone Metab"},{"issue":"3","key":"2026082903272089900_ref33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jbmr.3330","article-title":"Sclerostin antibody augments the anabolic bone formation response in a mouse model of mechanical tibial loading","volume":"33","author":"Morse","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"37","key":"2026082903272089900_ref34","doi-asserted-by":"publisher","first-page":"15048","DOI":"10.1073\/pnas.1203085109","article-title":"Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin","volume":"109","author":"Bonnet","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2026082903272089900_ref35","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.jbiomech.2009.08.030","article-title":"Local bone formation due to combined mechanical loading and intermittent hPTH-(1-34) treatment and its correlation to mechanical signal distributions","volume":"42","author":"Roberts","year":"2009","journal-title":"J Biomech"},{"issue":"18","key":"2026082903272089900_ref36","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"2026082903272089900_ref37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"2026082903272089900_ref38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2026082903272089900_ref39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9886","key":"2026082903272089900_ref40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet."},{"issue":"3","key":"2026082903272089900_ref41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrrheum.2018.5","article-title":"Osteoporosis: Romosozumab to rebuild the foundations of bone strength","volume":"14","author":"Ferrari","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2026082903272089900_ref42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jbmr.2044","article-title":"The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b","volume":"29","author":"Li","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2026082903272089900_ref43","volume-title":"45th European Calcified Tissue Society Congress","author":"Gerbaix"},{"key":"2026082903272089900_ref44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/bonekey.2014.13","article-title":"Combination therapy for osteoporosis: a reappraisal","volume":"3","author":"Cosman","year":"2014","journal-title":"Bonekey Rep"},{"issue":"9","key":"2026082903272089900_ref45","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026082903272089900_ref46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jbmr\/zjae057","article-title":"Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study","volume":"39","author":"Tripto-Shkolnik","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026082903272089900_ref47","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat Commun"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag053\/67381148\/zjag053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/915\/67381148\/zjag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/915\/67381148\/zjag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:27:27Z","timestamp":1787988447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/9\/915\/8526235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,17]]},"published-print":{"date-parts":[[2026,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag053","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,17]]}}}